H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value"

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $37.00 price target on Pharming Group (NASDAQ: PHAR)

The analyst commented, "Commercial durability remains a big part of the story, with Ruconest continuing to add patients despite increasing competition in HAE and Joenja uptake supporting steady growth. The most important near-term catalyst, in our opinion, is the upcoming Type A meeting with the FDA following the pediatric Joenja CRL, which should clarify whether existing PK/exposure data can address questions around lower pediatric dosing and define the regulatory path forward. We expect 2026 to be characterized by continued commercial growth alongside longer-term upside from pipeline programs, including leniolisib studies in broader PID populations and the pivotal napazimone FALCON trial... We believe that Pharming is well positioned to drive value through durable commercial revenues, meaningful near-term growth drivers, and a high-value late-stage pipeline. We believe this balanced profile supports near-term execution and longer-term upside."

For an analyst ratings summary and ratings history on Pharming Group click here. For more ratings news on Pharming Group click here.

Shares of Pharming Group closed at $15.88 yesterday.

You May Also Be Interested In

• BofA says convenience store sales trail broader retail channels
• Motorcar Parts of America (MPAA) PT Lowered to $16 at Freedom Broker
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results